icon-    folder.gif   Conference Reports for NATAP  
  IAS 2013: 7th IAS Conference on HIV
Pathogenesis Treatment and Prevention
June 30 - July 3 2013
Kuala Lumpur, Malaysia
Back grey_arrow_rt.gif
Phase 3 Assessment of Dolutegravir (DTG) 50 mg Twice Daily (BID) in HIV-1-Infected Subjects With Raltegravir (RAL) and/or Elvitegravir (EVG) Resistance in VIKING-3: Week 24 Results of All 183 Subjects Enrolled
  Reported by Jules Levin
IAS 2013 Kuala Lumpur June 30-July 3
G Nichols,1 A Lazzarin,2 F Maggiolo,3 G Penco,4 D Wright,5 A Mills,6 R Grossberg,7 J-M Molina,8 J Durant,9 G Pialoux,10 S Moreno,11 M Doroana,12 M Ait-Khaled,13 J Huang,14 S Min,1 C Vavro,1 J Yeo,13 on behalf of the VIKING-3 investigators
1GlaxoSmithKline, Research Triangle Park, NC, USA; 2San Raffaele Scientific Institute, Milan, Italy; 3Ospedale Riuniti, Bergamo, Italy; 4Universita degli Studi di Genova, Italy; 5Central Texas Clinical Research, Austin, TX, USA; 6Anthony Mills MD Inc, Los Angeles, CA, USA; 7Montefiore Medical Center, New York, NY, USA; 8Hopital Saint-Louis, Paris, France; 9Hopital de L'Archet, Nice, France; 10Hopital Tenon, Paris, France; 11Hospital Universitario Ramon y Cajal, Madrid, Spain; 12Hospital de Santa Maria, Lisbon, Portugal; 13-14GlaxoSmithKline, 13London, UK; 14Mississauga, ON, Canada